Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

CT-related radiation blamed for up to 2% of US cancers

December 1, 2007
By James Brice
James Brice
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

A New England Journal of Medicine review article is highlighting the cancer risks of computed tomography at the same time that hundreds of scientific presentations and new product announcements at the 2007 RSNA meeting are fueling the continued growth of multislice CT.

A New England Journal of Medicine review article is highlighting the cancer risks of computed tomography at the same time that hundreds of scientific presentations and new product announcements at the 2007 RSNA meeting are fueling the continued growth of multislice CT.

David J. Brenner, PhD, DSc, and Eric J. Hall, DPhil, DSc, both associated with the Center for Radiological Research at Columbia University, conclude from an examination of CT physics and often-quoted historical data from survivors of the Hiroshima and Nagasaki atomic bomb blasts that the growth of medical CT utilization may be responsible for 1.5% to 2% of US cancer cases.

They estimate that perhaps 20 million adults and more than 1 million children per year in the United States are irradiated unnecessarily from medical CT (N Engl J Med 357:2277-2284, 2007).

The rapid growth of CT utilization—from 3 million procedures in 1980 to 62 million scans per year in the mid-2000s—form that basis for Brenner and Hall's concerns. They say the risks for any one person are not large, but the increasing exposure to radiation may be a future public health issue.

Their analysis pegs that growth to the proliferation of multislice CT technology and screening applications for adults and children. They expressed concern about the growing popularity of CT for presurgical diagnosis of appendicitis for children, for example, because diagnostic ultrasound, a modality that involves no ionizing radiation, is probably equally effective for the same procedure.

They cite estimates indicating that 6% to 11% of CT studies are performed on children. A chart in the review indicates that a neonatal abdominal CT exposes a newborn infant to 20 mSv of radiation.

Screening is also an important motivation for increased CT use for asymptomatic adults, according to the authors. They predict that future utilization growth will arise from virtual CT colonoscopy, CT lung cancer screening, cardiac screening, and whole-body screening.

Citing atomic bomb survivor data, Brenner and Hall say that a substantial proportion of the 25,000 survivors received less than 50 mSv exposure, the equivalent of about three cardiac CT scans. A significant increase in the overall risk of cancer was recorded for the subgroup of atomic bomb survivors who received low doses of radiation in the 5 to 50 mSv range, they wrote.

"There is direct evidence from epidemiologic studies that the organ doses corresponding to a common CT study (two or three scans) result in an increased risk of cancer," they wrote. "The evidence is reasonably convincing for adults and very convincing for children."

Part of the issue, they wrote, "is that physicians often view CT studies in the same light as other radiologic procedures, even though radiation doses are typically much higher with CT than with other radiologic procedures."

In a recent survey of radiologist and ER physicians, they said, about 75% of the group significantly underestimated the radiation dose from a CT scan. Further, 53% of the radiologists and 91% of the ER physicians did not believe that CT scans increase the lifetime cancer risk.

In light of these findings, the authors said they welcomed the recent distribution among the medical community of the pamphlet "Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers." The pamphlet can be found on NCI's website: http://www.nci.nih.gov/cancertopics/causes/radiation-risks-pediatric-CT.

The authors recommend better equipment and techniques to lower radiation exposure and the alternative use of MRI and ultrasound, especially for infants and children. They urge physicians to avoid inappropriate CT utilization.

Skepticism from ACR

The American College of Radiology expressed skepticism about the article. In a release, ACR noted that no published research exists to support Brenner and Hall's claim that radiation from CT may cause up to 2% of all cancers in the United States. ACR challenged the correlation between atomic bomb blast data and controlled exposure to radiation involved with CT scanning.

Arl Van Moore, Jr., MD, chair of the ACR board of chancellors, worried that patients may mistakenly avoid what the ACR characterized as "life-saving medical imaging care," because of the article.

"They may be terribly confused and unduly distressed by some of the statements in this study," he said.

Michael Brant-Zawadzki, MD, of RSNA's public information advisor's network, said many radiologists agree that inappropriate CT scans are done because of medico-legal concerns and exploitation by profit-driven referring physicians and commercial imaging providers.

The theoretical risk of carcinogenesis from radiation discussed by Brenner and Hall has been debated for decades. Experts disagree over whether carcinogenesis occurs at the low dose levels generated by CT scanners, Dr. Brant-Zawadzki said.

CT has become the diagnostic workhorse in hospital and emergency room settings and has dramatically increased the diagnostic productivity of physicians, he said. In the ER, CT has replaced the physical exam to speed patient triage.

In contrast to Brenner and Hall's public health concerns about CT, Dr. Brant-Zawadzki stressed its contributions.

"It has saved countless thousands of lives," he said.

Articles in this issue

Third-line single-agent cetuximab ups overall survival
Modern multislice CT propels pancreas imaging forward
Sorafenib gets ok for liver cancer
Celgene to acquire Pharmion
Novacea halts ASCENT-2 trial
RT/temozolomide raises possibility of cure in glioblastoma
Brachytherapy as effective in younger as in older men
MMA not harming patients
Kinase inhibitor may prevent RT-induced lung injury
FDA approves lower starting dose for dasatinib for CML
Encouraging Avastin results in glioblastoma multiforme
Sunitinib is cost-effective in metastatic renal ca patients
The role of imaging in microsphere therapy of liver mets
Free website offers chemo order forms
MR tops x-ray and scintigraphy for detecting bone mets

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

Gina Mauro
June 9th 2025
Article

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.


The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Related Content

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

Gina Mauro
June 9th 2025
Article

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.


The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

Dylann Cohn-Emery
June 6th 2025
Article

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.